Intraoperative Margin Visualization Articles & Analysis
12 news found
The study’s findings validate the further exploration of the use of Perimeter’s wide-field Optical Coherence Tomography (WF-OCT) technology to visualize margins during head and neck surgeries. The research study, conducted at Mount Sinai Icahn School of Medicine, included 53 adult patients undergoing primary ablative surgery of the oral cavity or ...
Perimeter S-Series OCT received FDA 510(k) clearance in 2021 and is a medical imaging tool that uses Optical Coherence Tomography (OCT) to provide clinicians with cross-sectional, real-time margin visualization (1-2 mm below the surface) of an excised tissue specimen. ...
OnLume Inc., an early stage medical imaging company with unique technology for improving surgical precision, has been awarded a substantial grant from the U.S. National Institutes of Health (NIH)’s National Cancer Institute (NCI) to advance development of its proprietary device for Fluorescence-Guided Surgery (FGS). OnLume has developed novel FGS imaging technology to illuminate critical ...
BOSTON — May 24, 2022 — Activ Surgical™, a digital surgery pioneer, today announced the successful completion of an Institutional Review Board (IRB) study using its ActivSight™ intraoperative imaging module at the Jacobs School of Medicine and Biomedical Sciences at the University at Buffalo (UB) in New York. The 40-patient study was led by principal investigator Dr. ...
London, UK and Boston, MA – March 22, 2022 – Hikma Pharmaceuticals PLC (Hikma), the multinational pharmaceutical company, today announced that its venture capital arm, Hikma Ventures has led an $15 million USD round of financing for Activ Surgical, a pioneering digital surgery imaging startup that is developing groundbreaking interoperative surgical intelligence hardware and software. ...
Today marks yet another milestone in Activ Surgical’s history as we announce that the company was issued its third patent from the United States Patent and Trademark Office (USPTO) for our ActivSightTM interoperable imaging module. The ActivSight module is designed to interface with existing vision systems to enable surgeons to view in real-time critical physiological structures and ...
There are a slew of digital health startups looking to change the surgical space to make it more connected, from Hillrom's surgical communication tool to Activ Surgical’s solution that gives surgeons real-time intraoperative visual data. London-based virtual surgery platform Proximie is looking to tackle surgical connectivity challenges with its augmented reality, machine learning and ...
Ambareen Sheriff appointed as Vice President, Regulatory and Quality and Robin Stevens appointed as Non-Executive Director Novel, best-in-class agent for visualizing breast cancer margins to enter Phase III trial in 1H22 SAN DIEGO, CA – Avelas Biosciences, Inc. ...
Alume Biosciences, Inc., a clinical stage biotechnology company developing nerve-targeted pharmaceuticals for surgical and therapeutic use, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for its lead compound ALM-488. ALM-488 is an investigational fluorescently labelled nerve targeting pharmaceutical being developed as an adjunct for the ...
Food and Drug Administration (FDA) for pegloprastide (AVB-620) for the intraoperative detection and visualization of positive margins during breast cancer surgery. Pegloprastide is designed to deliver a fluorescent marker to cancer cells to aid surgeons in identifying positive margins in real time during surgery. Positive ...
nView medical Inc. (nView) today announced the U.S. Food and Drug Administration (FDA) clearance of nView s1, the company’s first imaging system, bringing breakthrough imaging technology to surgery. nView’s mission is to make surgery safer, faster, and consistently accurate by creating instant 3D information throughout the surgical procedure. nView s1 integrates the latest ...
Gauss Surgical, Inc., maker of Triton, the world’s first and only platform for real-time monitoring of surgical blood loss, today announced the close of its $12.6 million in Series B financing, bringing its total funding to $24.6 million. Providence Ventures, the investment arm of Providence Health & Services, the third largest not-for-profit health system in the United States, led the ...